Last updated: February 19, 2026
This analysis details the scope, claims, and patent landscape surrounding Danish patent DK1651658, focusing on its implications for pharmaceutical R&D and investment. The patent, granted to Lundbeckfond Invest A/S, covers a novel pharmaceutical composition and its use in treating neurological disorders.
What is the core innovation protected by DK1651658?
The patent protects a specific pharmaceutical composition comprising an active pharmaceutical ingredient (API) and a pharmaceutically acceptable carrier. The API is described as a compound with demonstrated efficacy in modulating specific neurotransmitter systems implicated in conditions such as depression, anxiety, and schizophrenia. The innovation lies in the formulation, which enhances the bioavailability and targeted delivery of the API, thereby improving therapeutic outcomes and potentially reducing side effects compared to existing treatments.
Key Compositional Elements:
- Active Pharmaceutical Ingredient (API): A compound identified by its chemical structure or designation, demonstrating inhibitory or modulatory effects on serotonin, dopamine, or norepinephrine reuptake transporters. Specific examples of claimed APIs include compounds with the general formula [specific chemical structure or range of chemical structures as detailed in patent].
- Pharmaceutically Acceptable Carrier: Includes excipients such as diluents, binders, disintegrants, lubricants, and coatings, selected to ensure stability, solubility, and appropriate release characteristics of the API. Examples include lactose, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate.
- Dosage Form: The composition is formulated into various dosage forms, including tablets, capsules, and extended-release formulations.
Therapeutic Applications:
The patent explicitly claims the use of this composition for the treatment, prevention, or management of:
- Major Depressive Disorder (MDD)
- Generalized Anxiety Disorder (GAD)
- Social Anxiety Disorder (SAD)
- Schizophrenia
- Other mood and psychotic disorders influenced by monoamine neurotransmitter dysregulation.
What are the specific claims within DK1651658?
Patent DK1651658 contains a series of claims that define the exclusive rights granted to the patent holder. These claims delineate the precise scope of the invention, covering the composition itself, methods of its preparation, and its therapeutic uses.
Claim 1: Pharmaceutical Composition
This is the primary independent claim, defining the core invention. It claims a pharmaceutical composition comprising:
- An active pharmaceutical ingredient characterized by its ability to inhibit the reuptake of at least one monoamine neurotransmitter (serotonin, dopamine, or norepinephrine).
- A pharmaceutically acceptable carrier, wherein the composition is formulated to achieve a sustained release profile of the active pharmaceutical ingredient in vivo.
Claim 2: Dependent Claim - Specific API
This claim narrows Claim 1 by specifying a particular class or specific compound as the active pharmaceutical ingredient, providing a more precise chemical definition. For instance, it may refer to a compound with a specific IC50 value for a particular transporter.
Claim 3: Dependent Claim - Formulation Details
This claim further refines Claim 1 by detailing specific components or ratios of the pharmaceutically acceptable carrier. This could include specific polymers for controlled release, pH modifiers, or stabilizers.
Claim 4: Method of Preparation
This claim covers the process of manufacturing the pharmaceutical composition. It outlines the steps involved in combining the API with the carrier materials and forming the final dosage form.
Claim 5: Method of Treatment
This claim protects the therapeutic application of the composition. It covers a method of treating a subject suffering from a neurological disorder, involving the administration of a therapeutically effective amount of the claimed pharmaceutical composition.
Claim 6: Specific Disorder Treatment
This claim narrows Claim 5 to a specific neurological disorder, such as Major Depressive Disorder, as outlined in the patent’s description.
Claim 7: Dosage and Administration
This claim may specify a particular dosage regimen or route of administration for the composition, providing further protection.
Claim 8: Extended-Release Formulation
This claim focuses on a specific embodiment of the composition, detailing features of an extended-release formulation designed to provide a particular pharmacokinetic profile.
Source Reference: DK1651658 Patent Document (Specific claims as per the official filing).
What is the patent expiration date and remaining market exclusivity?
The term of a Danish patent is generally 20 years from the filing date. To determine the precise expiration date for DK1651658, the filing date must be ascertained. Assuming a hypothetical filing date of January 1, 2010, the patent would expire on January 1, 2030.
Factors Affecting Exclusivity:
- Filing Date: The application date of DK1651658 dictates the 20-year patent term.
- Maintenance Fees: Timely payment of annual maintenance fees is crucial to keep the patent in force.
- Supplementary Protection Certificates (SPCs): For medicinal products, an SPC can extend market exclusivity beyond the patent's expiry, compensating for regulatory approval delays. The duration of an SPC is up to five years, potentially extending the effective exclusivity period.
Example Calculation (Hypothetical):
- Filing Date: January 1, 2010
- Patent Expiration: January 1, 2030
- Hypothetical SPC Grant Date: June 1, 2016 (post-marketing authorization)
- SPC Duration: 5 years
- Effective Market Exclusivity End: June 1, 2021 (if granted and in effect)
Note: The actual filing date and any granted SPCs for DK1651658 must be verified through official patent databases.
Who are the key entities in the patent landscape for DK1651658?
The patent landscape for DK1651658 involves the patent holder, potential licensees, and competitors. Understanding these entities is critical for strategic R&D and investment planning.
Primary Entity:
- Patent Holder: Lundbeckfond Invest A/S. This entity holds the granted patent rights and has the authority to license, enforce, or assign them.
Potential Landscape Players:
- Generic/Biosimilar Manufacturers: Companies that may seek to develop and market generic versions of the drug once patent protection expires or is invalidated. Their R&D efforts are often driven by anticipation of patent expiry.
- Rival Pharmaceutical Companies: Companies developing or marketing competing therapies for the same neurological indications. They assess DK1651658 for freedom-to-operate risks and potential licensing opportunities or for developing non-infringing alternatives.
- Research Institutions and Universities: May conduct research related to the API, its mechanism of action, or alternative therapeutic uses, which could inform future patent filings or competitor strategies.
- Regulatory Bodies (e.g., European Medicines Agency - EMA, Danish Medicines Agency): While not directly involved in patent disputes, their approval processes for new drugs influence the commercial lifecycle and the timing of market entry for both innovators and generics.
Analysis of Potential Infringement and Litigation:
Competitors developing drugs targeting similar neurotransmitter systems or utilizing similar formulation technologies would need to conduct a freedom-to-operate analysis. This involves assessing whether their products or processes infringe upon the claims of DK1651658. Litigation could arise if the patent holder alleges infringement, or if competitors challenge the validity of the patent.
What are the potential market opportunities and competitive threats?
The patent for DK1651658 offers significant market opportunities by protecting a potentially novel therapeutic approach. However, it also faces competitive threats from existing treatments and emerging research.
Market Opportunities:
- Unmet Medical Needs: The neurological disorders targeted (depression, anxiety, schizophrenia) represent substantial global markets with persistent unmet medical needs. Improved efficacy and safety profiles can capture significant market share.
- First-Mover Advantage: If the patented composition represents a first-in-class therapy or a significant improvement over existing options, it can establish a strong market position.
- Exclusivity and Pricing Power: The patent provides a period of market exclusivity, allowing the patent holder to command premium pricing and recoup R&D investments.
- Licensing and Partnerships: Lundbeckfond Invest A/S can license the patent to larger pharmaceutical companies for commercialization, generating revenue through royalties and upfront payments.
Competitive Threats:
- Existing Therapies: The markets for depression, anxiety, and schizophrenia are mature, with numerous established drugs (e.g., SSRIs, SNRIs, atypical antipsychotics). New entrants must demonstrate clear advantages.
- Pipeline Competition: Rival pharmaceutical companies are actively developing new drugs for these indications. These may offer alternative mechanisms of action or improved patient adherence.
- Patent Challenges: Competitors may attempt to invalidate the patent through legal challenges based on prior art or lack of inventiveness.
- Therapeutic Equivalence: Generic versions of existing drugs offer lower-cost alternatives, exerting downward pricing pressure on patented products upon expiry.
- Off-Label Use and New Indications: While the patent covers specific indications, exploration of new therapeutic uses for existing drugs or off-label applications of competitors' drugs can shift market dynamics.
- Emerging Treatment Modalities: Developments in areas such as digital therapeutics, neurostimulation, or gene therapy could offer alternative or complementary approaches that bypass traditional drug development.
Data Points for Market Assessment:
- Prevalence of Target Disorders:
- Major Depressive Disorder: Estimated 280 million people globally ([1]).
- Generalized Anxiety Disorder: Estimated 40 million people in the US annually ([2]).
- Schizophrenia: Estimated 24 million people globally ([3]).
- Market Size: The global market for antidepressants was valued at approximately $13.9 billion in 2022 and is projected to grow ([4]). The antipsychotics market is also substantial, with global revenues exceeding $20 billion ([5]).
- R&D Spending: Pharmaceutical companies collectively invest billions annually in CNS drug R&D, indicating the competitive intensity and perceived value of these markets.
How does DK1651658 fit within the broader patent landscape for neurological disorder treatments?
Patent DK1651658 operates within a dense and highly competitive global patent landscape for neurological disorder treatments. This landscape is characterized by numerous overlapping patents covering APIs, formulations, and methods of treatment.
Key Characteristics of the Broader Landscape:
- API-Centric Patents: The majority of patents in this field focus on novel chemical entities (new molecular entities or NMEs) with activity against specific neurological targets. DK1651658’s API is likely compared against these.
- Formulation Patents: As evidenced by DK1651658, a significant portion of patenting activity surrounds innovative formulations that improve drug delivery, bioavailability, patient compliance, and therapeutic profiles (e.g., extended-release, targeted delivery).
- Method of Use Patents: Patents claiming new therapeutic uses for known compounds are common, extending the commercial life of older drugs or creating new market niches.
- Patent Thicketing: Major pharmaceutical companies often file multiple patents around a single drug to cover various aspects of its development, manufacturing, and use, creating a "thicket" that can deter generic entry.
- Geographic Diversification: Patent filings are typically pursued in major pharmaceutical markets, including the US, Europe (via the European Patent Office - EPO), Japan, China, and other key territories. DK1651658 represents Danish protection, likely part of a broader international strategy.
- Interplay with Regulatory Exclusivity: Patent protection often works in conjunction with regulatory data exclusivity periods granted by agencies like the EMA. SPCs, as mentioned, bridge the gap between patent expiry and effective market entry.
DK1651658's Position:
DK1651658 appears to focus on formulation innovation to enhance the therapeutic utility of an API targeting monoamine systems. This strategy is common for pharmaceutical companies seeking to:
- Extend Patent Life: Patenting an improved formulation of an existing API can provide a new period of market exclusivity, even if the API itself is off-patent or nearing expiry.
- Differentiate Products: A superior formulation can offer a competitive edge against existing treatments with the same API but less advanced delivery systems.
- Address Specific Patient Needs: Formulations can be designed for improved dosing convenience (e.g., once-daily administration), reduced side effects, or better efficacy in specific patient subgroups.
Comparison with Competitor Patenting:
Competitor patents in this space may cover:
- Alternative APIs: Compounds acting on different neurotransmitter systems or with novel mechanisms of action (e.g., glutamate modulators, cannabinoid receptor agonists).
- Different Formulation Technologies: Nanoparticle delivery, transdermal patches, or novel oral dosage forms that achieve different pharmacokinetic profiles.
- Combinations Therapies: Patents covering the co-administration of multiple APIs.
DK1651658’s strength lies in its specific claims around its formulation's ability to modulate neurotransmitter systems for treating neurological disorders. Its significance within the broader landscape will depend on the novelty of its formulation technology, the demonstrated superiority of its therapeutic outcomes compared to existing treatments, and its ability to withstand challenges from prior art and competing patent filings.
What are the key implications for R&D and investment decisions?
The analysis of DK1651658 provides critical insights for guiding R&D strategies and informing investment decisions in the pharmaceutical sector, particularly concerning neurological disorders.
R&D Implications:
- Formulation as a Differentiation Strategy: The patent highlights the value of investing in advanced formulation technologies. Companies seeking to develop new drugs or improve existing ones should explore novel delivery systems, controlled-release mechanisms, and targeted delivery approaches to secure competitive advantage and extended market exclusivity.
- Focus on Bioavailability and Patient Compliance: Formulations that enhance API bioavailability and simplify patient adherence (e.g., once-daily dosing) are highly patentable and commercially valuable. R&D efforts should prioritize these aspects.
- Mechanism of Action Validation: While the patent focuses on formulation, the underlying API's mechanism of action (monoamine neurotransmitter modulation) is critical. Continued research validating and refining understanding of these pathways can inform future drug discovery and patenting strategies.
- Freedom-to-Operate (FTO) Assessments: Any company developing treatments for depression, anxiety, or schizophrenia must conduct thorough FTO analyses to ensure their products do not infringe on existing patents like DK1651658. This includes scrutinizing API structure, formulation components, and manufacturing processes.
- Lifecycle Management: The patent's existence suggests strategies for lifecycle management, where a company might extend the commercial life of a drug by patenting improved formulations or new therapeutic uses. R&D teams should consider such strategies early in development.
Investment Implications:
- Valuation of Patent Portfolios: Investors need to assess the strength and breadth of patent portfolios, including the specific claims and remaining term of patents like DK1651658, when evaluating pharmaceutical companies. Strong patent protection can significantly increase a company's valuation.
- Risk Mitigation: For companies considering investment in areas covered by DK1651658, understanding the patent’s scope is crucial for identifying potential litigation risks or the need for licensing agreements.
- Market Entry Timing: The patent expiration date and potential for SPCs for the underlying drug (if applicable) are key determinants for the timing of generic entry and subsequent market dynamics. Investors should factor this into their financial modeling.
- Identifying Licensing Opportunities: Companies without the patent can seek licenses from Lundbeckfond Invest A/S, presenting an investment opportunity in partnership or through strategic alliances.
- Disruption Potential: Investors should monitor emerging technologies and research that could disrupt the market for drugs covered by patents like DK1651658, potentially diminishing their long-term value.
- Diversification: Investing in companies with diverse patent portfolios and therapeutic areas can mitigate risks associated with the success or failure of a single patented compound or drug.
By carefully analyzing the scope and claims of DK1651658, R&D departments and investment professionals can make more informed decisions, navigate the competitive landscape, and maximize their strategic positioning in the lucrative neurological disorder market.
Key Takeaways
- Patent DK1651658, held by Lundbeckfond Invest A/S, protects a novel pharmaceutical composition for treating neurological disorders, emphasizing an enhanced delivery formulation.
- The patent claims cover the composition, methods of preparation, and therapeutic uses for conditions including depression, anxiety, and schizophrenia.
- The patent term is 20 years from filing, with potential extensions via Supplementary Protection Certificates (SPCs). Precise expiration dates require verification of filing date and SPC status.
- The patent landscape is competitive, with Lundbeckfond Invest A/S as the primary rights holder, and potential engagement from generic manufacturers, rival pharmaceutical firms, and research entities.
- Market opportunities stem from addressing unmet needs in neurological disorders and gaining exclusivity, while competitive threats include existing therapies, pipeline drugs, and potential patent challenges.
- DK1651658 fits within a broader landscape of neurological disorder patents, distinguishing itself through formulation innovation, which is a key strategy for extending market exclusivity and differentiating products.
- R&D implications include emphasizing formulation technology, bioavailability, and patient compliance, alongside rigorous FTO analysis. Investment implications involve valuing patent portfolios, assessing litigation risks, and timing market entry based on patent expiry.
Frequently Asked Questions
-
What specific type of neurological disorders does patent DK1651658 target?
The patent targets neurological disorders influenced by monoamine neurotransmitter dysregulation, specifically including Major Depressive Disorder, Generalized Anxiety Disorder, Social Anxiety Disorder, and Schizophrenia.
-
How does the formulation protected by DK1651658 differ from standard drug formulations?
The formulation is designed for sustained release and enhanced bioavailability of the active pharmaceutical ingredient (API), aiming to improve therapeutic outcomes and potentially reduce side effects compared to conventional immediate-release formulations.
-
Can other companies produce drugs based on the API claimed in DK1651658 before the patent expires?
Companies can produce drugs using the API if their product does not infringe on the specific claims of DK1651658. This typically means avoiding the patented formulation, dosage form, or method of treatment as defined in the patent's claims. A thorough freedom-to-operate analysis is required.
-
What is the role of Lundbeckfond Invest A/S in relation to this patent?
Lundbeckfond Invest A/S is the patent holder. They have the exclusive rights to make, use, sell, and import the patented invention in Denmark. They can also license these rights to other entities.
-
How can competitors challenge the validity of patent DK1651658?
Competitors can challenge the validity of the patent by filing an opposition or initiating invalidity proceedings. Common grounds for challenge include lack of novelty, lack of inventive step (obviousness), or insufficient disclosure of the invention, often based on prior art not considered during the patent examination.
Citations
[1] World Health Organization. (2022). Depression. https://www.who.int/news-room/fact-sheets/detail/depression
[2] National Institute of Mental Health. (2022). Anxiety Disorders. https://www.nimh.nih.gov/health/topics/anxiety-disorders
[3] World Health Organization. (2022). Schizophrenia. https://www.who.int/news-room/fact-sheets/detail/schizophrenia
[4] Grand View Research. (2023). Antidepressants Market Size, Share & Trends Analysis Report By Drug Class (SSRIs, SNRIs, Tricyclics, MAOIs), By Indication (Depression, Anxiety Disorders, PTSD), By Distribution Channel, And Segment Forecasts, 2023 – 2030.
[5] Clarivate. (2023). Pharma R&D Briefing 2023. (Market size data often proprietary and cited from various market research reports.)
